Dr. Welslau on the Benefits of Biosimilars in DLBCL


Manfred Welslau, MD, discusses​ the potential benefits of ​using biosimilars in diffuse large B-cell lymphoma.

Manfred Welslau, MD, Internal Medicine, Hematology and Oncology, Onkologie Aschaffenburg, discusses​ the potential benefits of ​using biosimilars in diffuse large B-cell lymphoma (DLBCL).

Due to low​er market price​s, biosimilars offer a more accessible ​options to patients in ​developed and underdeveloped countries, Welslau explains.

Notably, biosimilars have a different approval process compared with biologics​, says Welslau. If the biosimilar agentdemonstrates clinical similarity to the reference biologic and does not demonstrate clinically meaningful differences regarding safety and efficacy, only 1 confirmatory phase 3 study is required to receive FDA and European Medicines Agency approval, Welslau concludes.

Related Videos
Phillip J. Koo, MD
Daniel Petrylak, MD
Saad Z. Usmani, MD, MBA, FACP, FASCO, chief, Myeloma Service, Memorial Sloan Kettering Cancer Center
Ilyas Sahin, assistant professor, Medicine, Department of Medicine, Division of Hematology & Oncology, University of Florida College of Medicine
Bhagirathbhai Dholaria, MBBS, associate professor, medicine, Division of Hematology and Oncology, Vanderbilt University Medical Center
Pasi A. Jänne, MD, PhD, discusses an exploratory analysis from the FLAURA2 trial of osimertinib plus chemotherapy in treatment-naive, EGFR-mutant NSCLC.
Eric S. Christenson, MD
Debra L. Richardson, MD, FACS, FACOG
Michael J. Overman, MD
Bernard H. Bochner, MD, FACS